Earnings summaries and quarterly performance for Zoetis.
Executive leadership at Zoetis.
Kristin Peck
Detailed
Chief Executive Officer
CEO
JB
Jamie Brannan
Executive Vice President and Chief Commercial Officer
RP
Robert Polzer
Executive Vice President and President, Research and Development
RL
Roxanne Lagano
Executive Vice President, General Counsel and Corporate Secretary
WJ
Wetteny Joseph
Executive Vice President and Chief Financial Officer
Board of directors at Zoetis.
AL
Antoinette Leatherberry
Detailed
Director
FD
Frank D'Amelio
Detailed
Director
GH
Gavin Hattersley
Detailed
Director
GN
Gregory Norden
Detailed
Director
LP
Louise Parent
Detailed
Director
MS
Mark Stetter
Detailed
Director
MM
Michael McCallister
Detailed
Chair of the Board
PB
Paul Bisaro
Detailed
Director
SK
Sanjay Khosla
Detailed
Director
ST
Stephanie Tilenius
Detailed
Director
VB
Vanessa Broadhurst
Detailed
Director
WR
Willie Reed
Detailed
Director
Research analysts who have asked questions during Zoetis earnings calls.
CS
Christopher Schott
JPMorgan Chase & Co.
5 questions for ZTS
Also covers: ABBV, AMGN, AMRX +15 more
EW
Erin Wright
Morgan Stanley
5 questions for ZTS
Also covers: ALGN, BTSG, CAH +18 more
BV
Brandon Vazquez
William Blair & Company, L.L.C.
4 questions for ZTS
Also covers: ALGN, CBLL, CVRX +16 more
Jonathan Block
Stifel Financial Corp.
4 questions for ZTS
Also covers: ALGN, COO, CUTR +11 more
Michael Ryskin
Bank of America Merrill Lynch
4 questions for ZTS
Also covers: A, ALGN, AVTR +28 more
NT
Navann Ty
BNP Paribas S.A.
4 questions for ZTS
Also covers: COO, ELAN, EOLS +4 more
CL
Christopher LoBianco
TD Cowen
3 questions for ZTS
Also covers: NVAX
Daniel Clark
Leerink Partners
3 questions for ZTS
Also covers: CERT, ELAN, IDXX +3 more
David Westenberg
Piper Sandler
3 questions for ZTS
Also covers: ADPT, AKYA, BLLN +13 more
AA
Andrea Alfonso
UBS
2 questions for ZTS
Also covers: ELAN
BP
Balaji Prasad
Barclays
2 questions for ZTS
Also covers: ALVO, AMRX, ELAN +7 more
Daniel Christopher Clark
Leerink Partners
2 questions for ZTS
Also covers: DOCS, GDRX, IDXX
GS
Glen Santangelo
Jefferies
2 questions for ZTS
Also covers: ALGN, ANIP, BHC +9 more
JB
Jon Block
Stifel, Nicolaus & Company, Incorporated
2 questions for ZTS
Also covers: COO, DXCM, ELAN +1 more
MR
Michael Riskin
Bank of America
2 questions for ZTS
Also covers: IDXX, LH
NT
Navann Ty Dietschi
BNP Paribas
2 questions for ZTS
Also covers: COO, ELAN, EOLS +6 more
AZ
Andrea Zayco Narvaez Alfonso
UBS
1 question for ZTS
Also covers: ELAN, EVH, LFST
BV
Brandon Vasquez
William Blair & Company
1 question for ZTS
Also covers: HSIC, NVST
Chris
TD Cowen
1 question for ZTS
Also covers: CECO, SITE, UAA
KS
Kris Schott
JPMorgan Chase & Co.
1 question for ZTS
RY
Russell Yuan
William Blair
1 question for ZTS
Sidharth Sahoo
HSBC
1 question for ZTS
Steve Scala
Cowen
1 question for ZTS
Also covers: ABBV, AZN, BMY +6 more
Recent press releases and 8-K filings for ZTS.
Zoetis proposes $1.75 billion convertible senior notes offering
ZTS
Debt Issuance
Share Buyback
- Zoetis announced a proposed private offering of $1.75 billion aggregate principal amount of 0.25% convertible senior notes due 2029, with an option for an additional $250 million.
- Net proceeds are intended to fund capped call transactions, purchase shares of Zoetis common stock in privately negotiated transactions, and repurchase additional shares under its existing $6 billion buyback program by Q1 2026.
- The notes will bear interest at 0.25% per annum, payable semi-annually, and will mature on June 15, 2029, with conversion rights subject to specified conditions and settlement in cash, stock, or a combination thereof at Zoetis’s election.
Dec 18, 2025, 9:17 PM
Zoetis prices $1.75 billion convertible senior notes
ZTS
Debt Issuance
Share Buyback
Convertible Preferred Issuance
- Zoetis priced $1.75 billion of 0.25% convertible senior notes due 2029, with an option for an additional $250 million, expected to close December 18, 2025.
- Net proceeds of approximately $1,723.2 million (or $1,969.6 million if the option is exercised) will fund $1.6 billion of common stock repurchases (up to $1.8 billion) and capped call transactions.
- The notes carry a 0.25% coupon, mature June 15, 2029, and are initially convertible at 6.7476 shares per $1,000 principal (≈$148.20 per share).
- Zoetis entered capped call transactions with a cap price of $211.7150 per share (75% premium) to mitigate dilution on conversion.
Dec 16, 2025, 6:15 AM
Zoetis proposes $1.75 billion convertible senior notes offering
ZTS
Debt Issuance
Share Buyback
- Zoetis intends to offer $1.75 billion aggregate principal amount of convertible senior notes due June 15, 2029, with an option for up to an additional $250 million.
- Net proceeds will fund capped call transactions and repurchase common stock under its $6 billion share buyback program, with remaining repurchases expected by Q1 2026.
- The notes will be senior, unsecured, accrue interest semi-annually and, upon conversion, Zoetis may settle obligations in cash, shares, or a combination at its election.
Dec 15, 2025, 12:09 PM
Zoetis declares Q1 2026 dividend
ZTS
Dividends
- On December 11, 2025, Zoetis declared a $0.53 per share dividend for Q1 2026, a 6% increase from the quarterly rate paid in 2025.
- The dividend will be paid on March 3, 2026, to shareholders of record as of January 20, 2026.
Dec 11, 2025, 9:17 PM
Zoetis declares Q1 2026 dividend, approves 6% increase
ZTS
Dividends
- Zoetis’ Board approved a $0.53 per share dividend for Q1 2026, a 6% increase from the quarterly rate paid in 2025.
- The dividend will be paid on March 3, 2026 to holders of record as of January 20, 2026.
- Zoetis generated $9.3 billion in revenue in 2024 and has approximately 13,800 employees, underscoring its leading animal health franchise.
Dec 11, 2025, 9:15 PM
Zoetis presents at Piper Sandler 37th Annual Healthcare Conference
ZTS
Product Launch
Share Buyback
- Zoetis emphasized its science-to-scale R&D engine, leveraging AI, genetics and diagnostics to start development in target species, resulting in faster timelines and lower costs versus human health peers.
- The company plans to launch a blockbuster (> $100 M) product each year through 2029, starting with a long-acting Cytopoint in 2026 (USDA approval), renal CKD therapy in H2 2027, and oncology assets in 2028-29, opening $5 B+ in new markets.
- Chronic kidney disease (CKD) represents a $3 B–$4 B addressable market with no current treatments; Zoetis has seven assets (therapeutics and diagnostics) and expects its first CKD launch in 2027 to enable earlier intervention in dogs and cats.
- Librela in the U.S. shows stabilization with > 75% pet-owner satisfaction; Zoetis targets a return to growth in H2 2026 via veterinarian education, owner engagement and phase IV studies starting this quarter.
- Management highlighted strong core growth drivers (dermatology, parasiticide, pain, livestock), favorable pet-health trends and noted a gap between their conviction and the stock’s current valuation, maintaining disciplined share buybacks alongside business reinvestment.
Dec 4, 2025, 2:30 PM
Zoetis outlines robust R&D pipeline at Piper Sandler conference
ZTS
Product Launch
New Projects/Investments
- Zoetis highlighted its science-to-scale R&D engine, leveraging AI, genetics and diagnostics to accelerate animal health development, enabling 12 potential blockbusters (≥$100 M each) with annual launches through 2029.
- The renal CKD program targets a $3–4 B unmet market with no current treatments, comprising seven assets (therapeutics and diagnostics) and a first monoclonal antibody for dogs planned in H2 2027.
- Librela’s U.S. sales are expected to return to growth in H2 2026, supported by over 75% pet-owner satisfaction, veterinary education initiatives, and phase IV studies rolling out through 2026.
- Zoetis reiterated its capital allocation priorities: reinvesting in R&D, selective M&A, maintaining a strong balance sheet, and returning cash via dividends and buybacks amid what it sees as a disconnect between its pipeline prospects and current stock valuation.
Dec 4, 2025, 2:30 PM
Zoetis presents R&D strategy and 2026-2030 blockbuster pipeline
ZTS
Product Launch
Guidance Update
Share Buyback
- CEO Kristin Peck highlighted Zoetis’s science-to-scale R&D engine, starting in target species and leveraging AI, genetics, and diagnostics for faster, lower-cost development and high approval confidence.
- The company disclosed 12 blockbuster products (≥ $100 M) slated for 2026–2030, including a long-acting Cytopoint (USDA; 2026), a renal CKD therapy (2H 2027), and oncology assets in 2028–2030, unlocking over $5 billion in new addressable markets.
- Zoetis’s CKD portfolio targets a $3–4 billion market currently without treatments, featuring seven assets (therapeutics and diagnostics) with the first monoclonal antibody for dogs set to launch in 2027.
- Librela’s U.S. launch is stabilizing, with > 75% pet-owner satisfaction; Zoetis expects a return to growth in 2H 2026 through vet education, case studies, and ongoing phase IV studies.
- CFO Wetteny Joseph noted a modest 2025 guidance reduction due to softer derm/OA visits and competitive dynamics, and reaffirmed capital allocation priorities: reinvesting in R&D, selective M&A, maintaining a strong balance sheet, and disciplined share buybacks amid the stock’s valuation disconnect.
Dec 4, 2025, 2:30 PM
Zoetis presents innovation and market growth strategy
ZTS
- Zoetis projects the global Animal Health market to grow to ~$90 B by 2035, up from ~$50 B in 2024, driven by secular tailwinds in companion animals and re-accelerating livestock trends.
- The company’s R&D model delivers ~½ the development time, ~4× higher success rates, and 20–30× greater cost efficiency versus typical human health drug development.
- A diversified pipeline aims for annual major approvals across near- (<4 years), mid- (4–7 years), and long-term (>7 years) horizons, spanning categories like oncology, renal, and cardiology mAbs.
- Financial discipline underpins growth, with 8–9% revenue CAGR, 41–42% adjusted EBITDA margin, and 26–27% average ROIC over 2020–2024.
Dec 2, 2025, 1:30 PM
Zoetis unveils innovation pipeline and R&D update
ZTS
New Projects/Investments
Guidance Update
- Zoetis has 12 pipeline products with blockbuster potential and expects a major market approval every year over the next several years.
- The chronic kidney disease program includes seven active projects, combining monoclonal antibodies and diagnostics, with the first canine therapeutic approval slated for 2027.
- In veterinary oncology, Zoetis targets initial approvals in 2028–2029 for MAb- and diagnostics-based cancer treatments, and plans cardiology asset rollouts by 2030.
- The global animal health total addressable market is ~$50 billion today, projected to nearly double by 2035, underpinning Zoetis’s increased R&D investment.
Dec 2, 2025, 1:30 PM
Quarterly earnings call transcripts for Zoetis.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more